Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

OCGN | Ocugen Inc

Index	-	P/E	-	EPS (ttm)	-0.37	Insider Own	2.31%	Shs Outstand	256.49M	Perf Week	0.78%
Market Cap	103.39M	Forward P/E	-	EPS next Y	-0.29	Insider Trans	3.50%	Shs Float	250.55M	Perf Month	-12.29%
Income	-83.28M	PEG	-	EPS next Q	-0.07	Inst Own	19.06%	Short Float / Ratio	9.71% / 6.46	Perf Quarter	-23.13%
Sales	0.00M	P/S	-	EPS this Y	17.11%	Inst Trans	-2.91%	Short Interest	24.33M	Perf Half Y	-54.32%
Book/sh	0.27	P/B	1.47	EPS next Y	6.35%	ROA	-76.04%	Target Price	4.12	Perf Year	-77.85%
Cash/sh	0.28	P/C	1.46	EPS next 5Y	-	ROE	-90.34%	52W Range	0.39 - 2.09	Perf YTD	-68.99%
Dividend	-	P/FCF	-	EPS past 5Y	63.63%	ROI	-110.96%	52W High	-80.70%	Beta	3.87
Dividend %	-	Quick Ratio	5.46	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	3.36%	ATR	0.02
Employees	84	Current Ratio	5.46	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	38.12	Volatility	2.81% 4.71%
Optionable	Yes	Debt/Eq	0.09	EPS Q/Q	-6.65%	Profit Margin	-	Rel Volume	0.26	Prev Close	0.41
Shortable	Yes	LT Debt/Eq	0.07	Earnings	Aug 21 AMC	Payout	-	Avg Volume	3.76M	Price	0.40
Recom	1.00	SMA20	-3.64%	SMA50	-15.88%	SMA200	-48.92%	Volume	635,877	Change	-0.89%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-01-23	Upgrade	Chardan Capital Markets	Neutral → Buy	$3.50
Aug-23-22	Initiated	Mizuho	Buy	$5
Jun-15-22	Resumed	ROTH Capital	Buy	$8
Jun-02-22	Initiated	Cantor Fitzgerald	Overweight	$4.50
Jul-26-21	Initiated	Noble Capital Markets	Outperform
Jun-11-21	Downgrade	ROTH Capital	Buy → Neutral	$10 → $6
May-07-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-09-21	Downgrade	Chardan Capital Markets	Buy → Neutral	$0.70 → $13
Feb-04-21	Upgrade	H.C. Wainwright	Neutral → Buy	$4.50

Sep-27-23 07:30PM	Ocugen to Participate in Fireside Chat at Chardan s 7th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-21-23 07:30AM	Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board (GlobeNewswire)
Sep-20-23 08:00AM	Ocugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023 (GlobeNewswire)
Sep-13-23 08:15AM	Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA) (GlobeNewswire)
Sep-12-23 07:30PM	Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023 (GlobeNewswire)
09:48AM	Loading…
Aug-24-23 09:48AM	Ocugen, Inc. (NASDAQ:OCGN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-23-23 02:05AM	Q2 2023 Ocugen Inc Earnings Call (Thomson Reuters StreetEvents) +16.84%
Aug-22-23 12:00PM	Ocugen (OCGN) Q2 2023 Earnings Call Transcript (Motley Fool) -8.96%
Aug-21-23 04:32PM	Ocugen Provides Business Update with Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-18-23 04:39PM	Ocugen to Host Conference Call on Tuesday, August 22 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-25-23 08:58PM	3 Millionaire-Maker Growth Stocks to Buy Before the Window (InvestorPlace)
Jul-13-23 07:00AM	7 Biotech Stocks to Sell in July (InvestorPlace)
Jun-30-23 08:00AM	Ocugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly (GlobeNewswire)
Jun-09-23 04:05PM	Ocugen, Inc. Announces Adjournment of Annual Meeting of Shareholders (GlobeNewswire)
Jun-05-23 07:02AM	Ocugen, Inc. Announces Business Advisory Board (GlobeNewswire)
02:00PM	Loading…
May-25-23 02:00PM	Wall Street Expects These Stocks to Soar 175% and 545%. Should You Buy? (Motley Fool)
May-24-23 08:36AM	Ocugen, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock (GlobeNewswire) -35.05%
May-23-23 04:01PM	Ocugen, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
08:00AM	Ocugen to Present at BIO International Convention 2023 (GlobeNewswire)
May-05-23 03:00PM	Ocugen (OCGN) Q1 2023 Earnings Call Transcript (Motley Fool)
07:17AM	Ocugen: Q1 Earnings Snapshot (AP Finance)
07:00AM	Ocugen Provides Business Update with First Quarter 2023 Financial Results (GlobeNewswire)
Apr-28-23 07:00AM	Ocugen to Host Conference Call on Friday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2023 Financial Results (GlobeNewswire)
Apr-27-23 07:25AM	Ocugen Announces OCU410ST Receives Orphan Drug Designation for Treatment of ABCA4-Associated Retinopathies (GlobeNewswire)
Apr-26-23 06:30AM	Ocugen, Inc. to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference (GlobeNewswire)
Apr-20-23 08:00AM	Ocugen to Present at Association for Research in Vision and Ophthalmology 2023 Annual Meeting (GlobeNewswire) -5.79%
Apr-14-23 01:47PM	Ocugen Highlights Interim Data From Gene Therapy Study For Genetic Vision Loss Disorder (Benzinga) -5.97%
07:45AM	Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis (GlobeNewswire)
Apr-11-23 06:20PM	Ocugen to Host Virtual Investor & Analyst Event on April 14, 2023 (GlobeNewswire) +7.37%
Mar-31-23 08:15AM	Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress (GlobeNewswire)
08:00AM	Loading…
Mar-27-23 08:00AM	Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA) (GlobeNewswire)
Mar-07-23 08:00AM	Ocugen, Inc. to Participate in Fireside Chat at 35th Annual Roth Conference (GlobeNewswire)
Mar-06-23 07:02AM	Ocugen Appoints Quan A. Vu to Chief Financial Officer & Chief Business Officer (GlobeNewswire) -5.49%
Mar-02-23 07:02AM	Ocugen, Inc. (NASDAQ:OCGN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-01-23 06:16AM	Ocugen, Inc. (NASDAQ:OCGN): Is Breakeven Near? (Simply Wall St.)
02:17AM	Q4 2022 Ocugen Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-28-23 06:04PM	Why Ocugen Stock Eked Out a Win Today (Motley Fool)
04:00PM	Ocugen (OCGN) Q4 2022 Earnings Call Transcript (Motley Fool)
07:00AM	Ocugen Provides Business Update with Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-27-23 05:57PM	Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1 Clinical Trial Evaluating OCU200 for the Treatment of Diabetic Macular Edema (GlobeNewswire)
Feb-17-23 08:00AM	Ocugen to Present at Retinal Vascular Disease Drug Development Summit (GlobeNewswire)
Feb-16-23 05:30AM	More Likely to 5x First: Novavax vs. Ocugen (Motley Fool) -5.45%
Feb-15-23 04:30PM	Ocugen to Host Conference Call on Tuesday, February 28 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-04-23 05:30AM	1 Reason to Buy Ocugen in 2023 and 2 Reasons to Sell (Motley Fool)
Feb-03-23 11:18AM	7 Heavily Shorted Penny Stocks for Your Short-Squeeze Watch List (InvestorPlace)
Feb-01-23 01:55PM	3 Sorry Pharma Stocks to Sell in February Before Its Too Late (InvestorPlace)
08:00AM	Ocugen Appoints Quan A. Vu as Chief Business Officer (GlobeNewswire)
Jan-31-23 08:00AM	Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference (GlobeNewswire)
Jan-29-23 07:00AM	2 Struggling Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the Plague (Motley Fool)
Jan-26-23 05:21AM	3 of the Fastest-Growing Stocks on the Planet in 2023 (Motley Fool)
Jan-23-23 05:21AM	3 Under-the-Radar Stocks With 590% to 772% Upside in 2023, According to Wall Street (Motley Fool)
Jan-11-23 07:03AM	7 Loser Stocks to Short for Big Profits (InvestorPlace)
Jan-09-23 08:33AM	Ocugen Announces Encouraging Data From Late-Stage COVID-19 Vaccine Study (Benzinga)
06:22AM	UPDATE 2-Ocugen-Bharat Biotech COVID vaccine meets main goals in U.S. trial (Reuters)
06:16AM	Ocugen stock up 16% premarket after company announced positive results for its COVID vaccine (MarketWatch)
06:00AM	Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met (GlobeNewswire)
Dec-29-22 03:39PM	Why Shares of Ocugen Jumped Thursday (Motley Fool) +11.50%
Dec-25-22 03:58PM	7 Hot Meme Stocks of 2022 to Sell Before 2023 (InvestorPlace)
Dec-16-22 06:30AM	Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart® (GlobeNewswire) +5.52%
Dec-15-22 05:15PM	Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital Amaurosis (GlobeNewswire) -8.81%
Dec-13-22 08:00AM	Ocugen, Inc. to Ring the Nasdaq Stock Market Closing Bell (GlobeNewswire) +5.44%
Dec-07-22 08:00AM	Ocugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis (GlobeNewswire)
Nov-28-22 07:30AM	Ocugen to Present at 3rd Annual Dry AMD Therapeutics Summit (GlobeNewswire)
Nov-17-22 09:23AM	3 Stocks to Avoid Right Now (Motley Fool)
Nov-09-22 06:16PM	Why Ocugen Stock Wilted on Wednesday (Motley Fool) -9.76%
Nov-08-22 06:30PM	Why Ocugen Stock Popped by 7% on Tuesday (Motley Fool) +7.19%
01:00PM	Ocugen, Inc. (OCGN) Q3 2022 Earnings Call Transcript (Motley Fool)
07:30AM	Ocugen Provides Business Update & Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-07-22 08:17AM	Ocugen, Inc.'s (NASDAQ:OCGN) largest shareholders are individual investors with 58% ownership, institutions own 40% (Simply Wall St.)
Nov-02-22 05:21AM	3 High-Octane Growth Stocks With 357% to 571% Upside, According to Wall Street (Motley Fool) -6.47%
Nov-01-22 07:42PM	Warning! Dont Even Consider Buying These 7 Dead-Money Stocks (InvestorPlace)
Oct-27-22 07:30AM	Ocugen to Host Conference Call on Tuesday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2022 Financial Results (GlobeNewswire) -5.11%
Oct-19-22 07:30AM	Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022 (GlobeNewswire)
Oct-12-22 05:37PM	Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2 (GlobeNewswire)
Oct-06-22 09:25AM	Wall Street Thinks This Top 100 Robinhood Stock Could Skyrocket by 217% (Motley Fool)
08:00AM	Ocugen, Inc. to Present at Upcoming Vaccines, Cell & Gene Therapy Conferences (GlobeNewswire)
Sep-29-22 07:30AM	Ocugen, Inc. to Present at Chardans 6th Annual Genetic Medicines Conference (GlobeNewswire) -11.33%
Sep-28-22 12:28PM	Ocugen obtains exclusive license for nasal Covid-19 vaccine to complement Covaxin (American City Business Journals) +11.54%
09:44AM	Ocugen Inks US Development Pact For Its Intranasal COVID-19 Vaccine (Benzinga)
06:30AM	Ocugen Announces Agreement With Washington University in St. Louis for Commercialization of Intranasal COVID-19 Vaccine in U.S., Europe, and Japan (GlobeNewswire)
Sep-16-22 05:07PM	Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.05%
Sep-14-22 06:30AM	Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology (GlobeNewswire)
Sep-08-22 07:30AM	Ocugen CSO to Participate in 3rd Annual Gene Therapy for Ophthalmic Disorders Conference (GlobeNewswire)
Sep-06-22 07:30AM	Ocugen, Inc. to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) -7.92%
Sep-01-22 06:28PM	Why Ocugen Stock Topped the Market Today (Motley Fool)
07:30AM	Ocugen Appoints Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, as Chief Medical Officer and Promotes Arun Upadhyay, PhD, to Chief Scientific Officer (GlobeNewswire)
Aug-24-22 03:36PM	Why Ocugen Stock Is Racing Higher Today (Motley Fool) +12.50%
Aug-23-22 09:08AM	This COVID-19 Shot Stock Could Have Eye Disease Gene Therapy As Significant Driver, Mizuho Analyst Says (Benzinga) +9.40%
Aug-13-22 09:45AM	Here's How This Beaten-Down Stock Could 10X by 2024 (Motley Fool)
Aug-12-22 10:30AM	1 Robinhood Stock to Avoid Right Now (Motley Fool) +5.97%
07:30AM	Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference (GlobeNewswire)
Aug-06-22 05:31AM	Ocugen, Inc. (OCGN) Q2 2022 Earnings Call Transcript (Motley Fool)
Aug-05-22 07:30AM	Ocugen Provides Business Update & Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-03-22 05:06PM	Ocugen Q2 Preview: Rebound Quarter Inbound? (Zacks)
Jul-29-22 03:27PM	Analysts Expect Breakeven For Ocugen, Inc. (NASDAQ:OCGN) Before Long (Simply Wall St.)
07:30AM	Ocugen To Host Conference Call on Friday, August 5 at 8:30 a.m. ET to Discuss Business Updates and Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-14-22 12:30PM	Why Ocugen, Sorrento Therapeutics, and VBI Vaccines Are on the Move Today (Motley Fool) -9.62%
Jul-13-22 12:25PM	Why Ocugen Is Climbing Today (Motley Fool) +5.82%
Jul-12-22 11:20AM	Why Ocugen Stock Is Sinking Today (Motley Fool)
Jul-08-22 04:48PM	Why Ocugen Stock Ascended Today (Motley Fool) +13.14%

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zhang Junge	Director	Jun 14	Buy	0.50	200,278	99,999	1,077,182	Jun 16 04:22 PM
Musunuri Shankar	Chief Executive Officer	Feb 16	Option Exercise	0.33	100,000	33,000	2,290,073	Feb 17 05:11 PM
Musunuri Shankar	Chief Executive Officer	Feb 16	Sale	1.08	100,000	108,000	2,190,073	Feb 17 05:11 PM
Musunuri Shankar	Chief Executive Officer	Jan 17	Option Exercise	0.51	100,000	51,000	2,327,950	Jan 19 04:12 PM
Musunuri Shankar	Chief Executive Officer	Jan 17	Sale	1.28	100,000	128,000	2,227,950	Jan 19 04:12 PM
Musunuri Shankar	Chief Executive Officer	Dec 16	Option Exercise	0.51	95,809	48,863	848,349	Dec 20 04:07 PM
Musunuri Shankar	Chief Executive Officer	Dec 16	Sale	1.43	95,809	137,007	752,540	Dec 20 04:07 PM
Musunuri Shankar	Chief Executive Officer	Oct 14	Option Exercise	0.51	100,000	51,000	852,540	Oct 14 04:15 PM
Musunuri Shankar	Chief Executive Officer	Oct 14	Sale	1.66	100,000	166,000	752,540	Oct 14 04:15 PM
Kumar Ramesh	Director	Oct 06	Option Exercise	0.51	4,500	2,295	4,500	Oct 07 04:06 PM
Kumar Ramesh	Director	Oct 06	Sale	1.83	4,500	8,235	0	Oct 07 04:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OCGN | Ocugen Inc

Upgrade your FINVIZ experience